Terri Johnson

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

Nicole Mayer-Hamblett, Félix Ratjen, Renee Russell et al. · The Lancet Respiratory Medicine · 2022 · 116 citations · Full text

Medicine, Hypertonic Saline, Dornase Alfa +1

Inhaled hypertonic saline in preschool children with cystic fibrosis (SHIP): a multicentre, randomised, double-blind, placebo-controlled trial

Félix Ratjen, Stephanie D. Davis, Sanja Stanojevic et al. · The Lancet Respiratory Medicine · 2019 · 111 citations

Pediatrics, Pediatric Lung Disease, Placebo-controlled Trial +3

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation

Shahid Sheikh, Frederick R. Long, Karen McCoy et al. · Journal of Cystic Fibrosis · 2014 · 51 citations · Full text

G551d Mutation, Tomography Correlates, Cystic Fibrosis Patients +3

Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation

Shahid Sheikh, Frederick R. Long, Karen McCoy et al. · Clinical Otolaryngology · 2014 · 39 citations

Clinical change 2 years from start of elexacaftor‐tezacaftor‐ivacaftor in severe cystic fibrosis

Karen McCoy, Jill E Blind, Terri Johnson et al. · Pediatric Pulmonology · 2023 · 30 citations